Our client, a renowned public research institute, wanted to explore the business opportunities presented by aptamer screening and drug-discovery technology. To gain data-driven insights and identify the most suitable commercialization route, it sought an accurate analysis of the technology’s adoption trends, market growth, and competitive patent landscape.

Business challenge

Our client wanted to explore the business opportunities presented by aptamer screening and drug-discovery technology. To gain data-driven insight and identify the most suitable commercialization route, it sought an accurate analysis of the technology’s adoption trends, market growth, and competitive patent landscape.

Solution

Being an established technology and innovation research leader, with over 18 years of demonstrated expertise in market and IP research, Netscribes was chosen to meet the requirement.

We took a multi-pronged approach for the study, which included the following steps:

1. Competitive benchmarking and market analysis:

    • Based on an in-depth study of the technology features and applications, regulatory environment, and a comparative analysis of competing technologies, we deduced the potential market opportunity for aptamer screening and drug-discovery technology.

2. Patent analysis:

    • To ensure that the client does not infringe on others’ patent rights, we assessed its patent publication across different geographies and highlighted the potential infringement scenario.

3. Partnership strategies:

    Lastly, we studied the potential target market and proposed a list of entities that could be considered for collaboration or technology out-licensing.

Results delivered

Based on the insights gathered through the patent study, market and competitive analysis, and technology landscape study, we provided three commercialization routes along with the potential revenue each could generate.

1. Collaborative approach:

    • Partnership with pharmaceutical companies to develop therapeutic aptamers

2. Out-licensing model:

    • Out-license the technology to other companies that offer custom aptamer development services

3. Spin-out model:

    Establish an in-house drug discovery spinout

Benefit

Netscribes’ comprehensive research and analysis gave the client a very clear understanding of the market potential of its innovation. Based on our recommendations, it decided to focus on an in-house drug discovery spin-out model and soon partnered with a leading pharmaceutical firm, for further development and the commercialization of its innovation.

Download this case study to find out how Netscribes’ comprehensive research and analysis gave the client a clear understanding of the market potential of its innovation and form the right partnerships for further development.

Download the Case Study

    +1
    • United States+1
    • United Kingdom+44
    • Afghanistan (‫افغانستان‬‎)+93
    • Albania (Shqipëri)+355
    • Algeria (‫الجزائر‬‎)+213
    • American Samoa+1684
    • Andorra+376
    • Angola+244
    • Anguilla+1264
    • Antigua and Barbuda+1268
    • Argentina+54
    • Armenia (Հայաստան)+374
    • Aruba+297
    • Australia+61
    • Austria (Österreich)+43
    • Azerbaijan (Azərbaycan)+994
    • Bahamas+1242
    • Bahrain (‫البحرين‬‎)+973
    • Bangladesh (বাংলাদেশ)+880
    • Barbados+1246
    • Belarus (Беларусь)+375
    • Belgium (België)+32
    • Belize+501
    • Benin (Bénin)+229
    • Bermuda+1441
    • Bhutan (འབྲུག)+975
    • Bolivia+591
    • Bosnia and Herzegovina (Босна и Херцеговина)+387
    • Botswana+267
    • Brazil (Brasil)+55
    • British Indian Ocean Territory+246
    • British Virgin Islands+1284
    • Brunei+673
    • Bulgaria (България)+359
    • Burkina Faso+226
    • Burundi (Uburundi)+257
    • Cambodia (កម្ពុជា)+855
    • Cameroon (Cameroun)+237
    • Canada+1
    • Cape Verde (Kabu Verdi)+238
    • Caribbean Netherlands+599
    • Cayman Islands+1345
    • Central African Republic (République centrafricaine)+236
    • Chad (Tchad)+235
    • Chile+56
    • China (中国)+86
    • Christmas Island+61
    • Cocos (Keeling) Islands+61
    • Colombia+57
    • Comoros (‫جزر القمر‬‎)+269
    • Congo (DRC) (Jamhuri ya Kidemokrasia ya Kongo)+243
    • Congo (Republic) (Congo-Brazzaville)+242
    • Cook Islands+682
    • Costa Rica+506
    • Côte d’Ivoire+225
    • Croatia (Hrvatska)+385
    • Cuba+53
    • Curaçao+599
    • Cyprus (Κύπρος)+357
    • Czech Republic (Česká republika)+420
    • Denmark (Danmark)+45
    • Djibouti+253
    • Dominica+1767
    • Dominican Republic (República Dominicana)+1
    • Ecuador+593
    • Egypt (‫مصر‬‎)+20
    • El Salvador+503
    • Equatorial Guinea (Guinea Ecuatorial)+240
    • Eritrea+291
    • Estonia (Eesti)+372
    • Ethiopia+251
    • Falkland Islands (Islas Malvinas)+500
    • Faroe Islands (Føroyar)+298
    • Fiji+679
    • Finland (Suomi)+358
    • France+33
    • French Guiana (Guyane française)+594
    • French Polynesia (Polynésie française)+689
    • Gabon+241
    • Gambia+220
    • Georgia (საქართველო)+995
    • Germany (Deutschland)+49
    • Ghana (Gaana)+233
    • Gibraltar+350
    • Greece (Ελλάδα)+30
    • Greenland (Kalaallit Nunaat)+299
    • Grenada+1473
    • Guadeloupe+590
    • Guam+1671
    • Guatemala+502
    • Guernsey+44
    • Guinea (Guinée)+224
    • Guinea-Bissau (Guiné Bissau)+245
    • Guyana+592
    • Haiti+509
    • Honduras+504
    • Hong Kong (香港)+852
    • Hungary (Magyarország)+36
    • Iceland (Ísland)+354
    • India (भारत)+91
    • Indonesia+62
    • Iran (‫ایران‬‎)+98
    • Iraq (‫العراق‬‎)+964
    • Ireland+353
    • Isle of Man+44
    • Israel (‫ישראל‬‎)+972
    • Italy (Italia)+39
    • Jamaica+1
    • Japan (日本)+81
    • Jersey+44
    • Jordan (‫الأردن‬‎)+962
    • Kazakhstan (Казахстан)+7
    • Kenya+254
    • Kiribati+686
    • Kosovo+383
    • Kuwait (‫الكويت‬‎)+965
    • Kyrgyzstan (Кыргызстан)+996
    • Laos (ລາວ)+856
    • Latvia (Latvija)+371
    • Lebanon (‫لبنان‬‎)+961
    • Lesotho+266
    • Liberia+231
    • Libya (‫ليبيا‬‎)+218
    • Liechtenstein+423
    • Lithuania (Lietuva)+370
    • Luxembourg+352
    • Macau (澳門)+853
    • Macedonia (FYROM) (Македонија)+389
    • Madagascar (Madagasikara)+261
    • Malawi+265
    • Malaysia+60
    • Maldives+960
    • Mali+223
    • Malta+356
    • Marshall Islands+692
    • Martinique+596
    • Mauritania (‫موريتانيا‬‎)+222
    • Mauritius (Moris)+230
    • Mayotte+262
    • Mexico (México)+52
    • Micronesia+691
    • Moldova (Republica Moldova)+373
    • Monaco+377
    • Mongolia (Монгол)+976
    • Montenegro (Crna Gora)+382
    • Montserrat+1664
    • Morocco (‫المغرب‬‎)+212
    • Mozambique (Moçambique)+258
    • Myanmar (Burma) (မြန်မာ)+95
    • Namibia (Namibië)+264
    • Nauru+674
    • Nepal (नेपाल)+977
    • Netherlands (Nederland)+31
    • New Caledonia (Nouvelle-Calédonie)+687
    • New Zealand+64
    • Nicaragua+505
    • Niger (Nijar)+227
    • Nigeria+234
    • Niue+683
    • Norfolk Island+672
    • North Korea (조선 민주주의 인민 공화국)+850
    • Northern Mariana Islands+1670
    • Norway (Norge)+47
    • Oman (‫عُمان‬‎)+968
    • Pakistan (‫پاکستان‬‎)+92
    • Palau+680
    • Palestine (‫فلسطين‬‎)+970
    • Panama (Panamá)+507
    • Papua New Guinea+675
    • Paraguay+595
    • Peru (Perú)+51
    • Philippines+63
    • Poland (Polska)+48
    • Portugal+351
    • Puerto Rico+1
    • Qatar (‫قطر‬‎)+974
    • Réunion (La Réunion)+262
    • Romania (România)+40
    • Russia (Россия)+7
    • Rwanda+250
    • Saint Barthélemy+590
    • Saint Helena+290
    • Saint Kitts and Nevis+1869
    • Saint Lucia+1758
    • Saint Martin (Saint-Martin (partie française))+590
    • Saint Pierre and Miquelon (Saint-Pierre-et-Miquelon)+508
    • Saint Vincent and the Grenadines+1784
    • Samoa+685
    • San Marino+378
    • São Tomé and Príncipe (São Tomé e Príncipe)+239
    • Saudi Arabia (‫المملكة العربية السعودية‬‎)+966
    • Senegal (Sénégal)+221
    • Serbia (Србија)+381
    • Seychelles+248
    • Sierra Leone+232
    • Singapore+65
    • Sint Maarten+1721
    • Slovakia (Slovensko)+421
    • Slovenia (Slovenija)+386
    • Solomon Islands+677
    • Somalia (Soomaaliya)+252
    • South Africa+27
    • South Korea (대한민국)+82
    • South Sudan (‫جنوب السودان‬‎)+211
    • Spain (España)+34
    • Sri Lanka (ශ්‍රී ලංකාව)+94
    • Sudan (‫السودان‬‎)+249
    • Suriname+597
    • Svalbard and Jan Mayen+47
    • Swaziland+268
    • Sweden (Sverige)+46
    • Switzerland (Schweiz)+41
    • Syria (‫سوريا‬‎)+963
    • Taiwan (台灣)+886
    • Tajikistan+992
    • Tanzania+255
    • Thailand (ไทย)+66
    • Timor-Leste+670
    • Togo+228
    • Tokelau+690
    • Tonga+676
    • Trinidad and Tobago+1868
    • Tunisia (‫تونس‬‎)+216
    • Turkey (Türkiye)+90
    • Turkmenistan+993
    • Turks and Caicos Islands+1649
    • Tuvalu+688
    • U.S. Virgin Islands+1340
    • Uganda+256
    • Ukraine (Україна)+380
    • United Arab Emirates (‫الإمارات العربية المتحدة‬‎)+971
    • United Kingdom+44
    • United States+1
    • Uruguay+598
    • Uzbekistan (Oʻzbekiston)+998
    • Vanuatu+678
    • Vatican City (Città del Vaticano)+39
    • Venezuela+58
    • Vietnam (Việt Nam)+84
    • Wallis and Futuna (Wallis-et-Futuna)+681
    • Western Sahara (‫الصحراء الغربية‬‎)+212
    • Yemen (‫اليمن‬‎)+967
    • Zambia+260
    • Zimbabwe+263
    • Åland Islands+358

    We respect your right to data privacy and security. You may unsubscribe from our communications at any time. For more information, check out our Privacy Policy.